Lisocabtagene Maraleucel Delivers Deep, Durable Efficacy in Chronic Lymphocytic Leukemia
May 30th 2023Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.
Read More
Expert: Though Patients Don’t Always See Savings With Biosimilars, New Policies Could Improve Access
May 15th 2023Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the role biosimilars are playing in the pharmaceutical market as well as in patient access.
Watch
Expert: Pharmacy, Medical Benefit Adoption of Biosimilars Present Different Challenges
May 2nd 2023Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the biosimilars landscape and where biosimilars fall in the process of pharmacy and medical benefit adoption.
Watch